Vitamin D and cancer risk and mortality: State of the science, gaps, and challenges

Epidemiologic Reviews

Volumn 39, Issue 1, 2017, Pages 28-48

  Mondul, Alison M ^a   Weinstein, Stephanie J ^a   Layne, Tracy M ^a   Albanes, Demetrius ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Genetics; Incidence; Mortality; Neoplasms; Prospective studies; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL 24 HYDROXYLASE; RETINOID X RECEPTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR; 25-HYDROXYVITAMIN D;

ARTICLE; BLACK PERSON; BLADDER CANCER; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; COLORECTAL CANCER; ESOPHAGUS CANCER; GENETIC VARIATION; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS (TOPIC); MORTALITY; OVARY CANCER; PANCREAS CANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SECONDARY PREVENTION; SKIN CANCER; STOMACH CANCER; SYSTEMATIC REVIEW (TOPIC); UTERUS CANCER; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLADDER TUMOR; BLOOD; COLORECTAL TUMOR; DIETARY SUPPLEMENT; FEMALE; MALE; NEOPLASM; PANCREAS TUMOR; PROSTATE TUMOR; PROTECTION; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AFRICAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PROTECTIVE FACTORS; RISK FACTORS; URINARY BLADDER NEOPLASMS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 85026415661     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxx005     Document Type: Article

References (149)

1. Garland FC, Garland CF, Gorham ED, et al. Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation. Prev Med. 1990;19(6):614-622.
2. Giovannucci E. The epidemiology of Vitamin D and cancer incidence and mortality: A review (United States). Cancer Causes Control. 2005;16(2):83-95.
3. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19(2):73-78.
4. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79(3):362-371.
5. Intitute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
6. McCullough ML, Weinstein SJ, Freedman DM, et al. Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):21-35.
7. Gandini S, Boniol M, Haukka J, et al. Meta-Analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011;128(6):1414-1424.
8. Lee JE, Li H, Chan AT, et al. Circulating levels of Vitamin D and colon and rectal cancer: The Physicians' Health Study and a meta-Analysis of prospective studies. Cancer Prev Res (Phila). 2011;4(5):735-743.
9. Ma Y, Zhang P, Wang F, et al. Association between Vitamin D and risk of colorectal cancer: A systematic review of prospective studies. J Clin Oncol. 2011;29(28):3775-3782.
10. Touvier M, Chan DS, Lau R, et al. Meta-Analyses of Vitamin D intake, 25-hydroxyvitamin D status, Vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20(5):1003-1016.
11. Chandler PD, Buring JE, Manson JE, et al. Circulating Vitamin D levels and risk of colorectal cancer in women. Cancer Prev Res (Phila). 2015;8(8):675-682.
12. Weinstein SJ, Purdue MP, Smith-Warner SA, et al. Serum 25-hydroxyvitamin D, Vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer. 2015;136(6): E654-E664.
13. Weinstein SJ, Yu K, Horst RL, et al. Serum 25- hydroxyvitamin D and risks of colon and rectal cancer in Finnish men. Am J Epidemiol. 2011;173(5):499-508.
14. Shao T, Klein P, Grossbard ML. Vitamin D and breast cancer. Oncologist. 2012;17(1):36-45.
15. Yin L, Grandi N, Raum E, et al. Meta-Analysis: serumvitaminD and breast cancer risk. Eur J Cancer. 2010;46(12):2196-2205.
16. Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: A meta-Analysis. Br J Cancer. 2014;110(11):2772-2784.
17. Bauer SR, Hankinson SE, Bertone-Johnson ER, et al. Plasma Vitamin D levels, menopause, and risk of breast cancer: doseresponse meta-Analysis of prospective studies. Medicine (Baltimore). 2013;92(3):123-131.
18. Wang D, Vélez de-la-Paz, OI, Zhai JX, et al. Serum 25- hydroxyvitamin D and breast cancer risk: A meta-Analysis of prospective studies. Tumour Biol. 2013;34(6):3509-3517.
19. Kim Y, Franke AA, Shvetsov YB, et al. Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: A nested case-control study in the Multiethnic Cohort Study. BMC Cancer. 2014; 14:29.
20. Skaaby T, Husemoen LL, Thuesen BH, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev. 2014; 23(7):1220-1229.
21. Xu Y, Shao X, Yao Y, et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-Analysis. J Cancer Res Clin Oncol. 2014;140(9):1465-1477.
22. Kristal AR, Till C, Song X, et al. Plasma Vitamin D and prostate cancer risk: Results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1494-1504.
23. Schenk JM, Till CA, Tangen CM, et al. Serum 25- hydroxyvitamin D concentrations and risk of prostate cancer: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1484-1493.
24. Zhang H, Zhang H, Wen X, et al. Vitamin D deficiency and increased risk of bladder carcinoma: A meta-Analysis. Cell Physiol Biochem. 2015;37(5):1686-1692.
25. Zhao Y, Chen C, Pan W, et al. Comparative efficacy of Vitamin D status in reducing the risk of bladder cancer: A systematic review and network meta-Analysis. Nutrition. 2016;32(5):515-523.
26. Chen GC, Zhang ZL, Wan Z, et al. Circulating 25-hydroxyvitamin D and risk of lung cancer: A doseresponse meta-Analysis. Cancer Causes Control. 2015; 26(12):1719-1728.
27. Zhang L, Wang S, Che X, et al. Vitamin D and lung cancer risk: A comprehensive review and meta-Analysis. Cell Physiol Biochem. 2015;36(1):299-305.
28. Yin L, Grandi N, Raum E, et al. Meta-Analysis: circulating Vitamin D and ovarian cancer risk. Gynecol Oncol. 2011; 121(2):369-375.
29. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):81-93.
30. Wolpin BM, Ng K, Bao Y, et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(1):82-91.
31. Caini S, Boniol M, Tosti G, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: A comprehensive review and meta-Analysis. Eur J Cancer. 2014;50(15):2649-2658.
32. Gallicchio L, Helzlsouer KJ, Chow WH, et al. Circulating 25- hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):10-20.
33. Abnet CC, Chen Y, Chow WH, et al. Circulating 25- hydroxyvitamin D and risk of esophageal and gastric cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):94-106.
34. Gallicchio L, Moore LE, Stevens VL, et al. Circulating 25- hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):47-57.
35. Purdue MP, Freedman DM, Gapstur SM, et al. Circulating 25-hydroxyvitamin D and risk of non-Hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):58-69.
36. Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, et al. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):36-46.
37. Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25- hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem. 2013;59(5):771-780.
38. Muller DC, Fanidi A, Midttun O, et al. Circulating 25- hydroxyvitamin D3 in relation to renal cell carcinoma incidence and survival in the EPIC cohort. Am J Epidemiol. 2014;180(8):810-820.
39. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev. 2014;(6):CD007469.
40. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating Vitamin D levels. Hum Mol Genet. 2010;19(13):2739-2745.
41. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of Vitamin D insufficiency: A genome-wide association study. Lancet. 2010;376(9736):180-188.
42. Gnagnarella P, Pasquali E, Serrano D, et al. Vitamin D receptor polymorphism FokI and cancer risk: A comprehensive meta-Analysis. Carcinogenesis. 2014;35(9):1913-1919.
43. Raimondi S, Pasquali E, Gnagnarella P, et al. BsmI polymorphism of Vitamin D receptor gene and cancer risk: A comprehensive meta-Analysis. Mutat Res. 2014;769:17-34.
44. Serrano D, Gnagnarella P, Raimondi S, et al. Meta-Analysis on Vitamin D receptor and cancer risk: focus on the role of TaqI, ApaI, and Cdx2 polymorphisms. Eur J Cancer Prev. 2016;25(1):85-96.
45. Kostner K, Denzer N, Muller CS, et al. The relevance of Vitamin D receptor (VDR) gene polymorphisms for cancer: A review of the literature. Anticancer Res. 2009;29(9): 3511-3536.
46. Arem H, Yu K, Xiong X, et al. Vitamin D metabolic pathway genes and pancreatic cancer risk. PLoS One. 2015;10(3): E0117574.
47. Ashmore JH, Gallagher CJ, Lesko SM, et al. No association between Vitamin D intake, VDR polymorphisms, and colorectal cancer in a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2015;24(10): 1635-1637.
48. Clendenen TV, Ge W, Koenig KL, et al. Genetic polymorphisms in Vitamin D metabolism and signaling genes and risk of breast cancer: A nested case-control study. PLoS One. 2015;10(10):e0140478.
49. Dorjgochoo T, Delahanty R, Lu W, et al. Common genetic variants in the Vitamin D pathway including genome-wide associated variants are not associated with breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2313-2316.
50. Gilbert R, Bonilla C, Metcalfe C, et al. Associations of Vitamin D pathway genes with circulating 25- hydroxyvitamin-D, 1, 25-dihydroxyvitamin-D, and prostate cancer: A nested case-control study. Cancer Causes Control. 2015;26(2):205-218.
51. Kong J, Xu F, Qu J, et al. Genetic polymorphisms in the Vitamin D pathway in relation to lung cancer risk and survival. Oncotarget. 2015;6(4):2573-2582.
52. Mahmoudi T, Karimi K, Arkani M, et al. Lack of associations between Vitamin D metabolism-related gene variants and risk of colorectal cancer. Asian Pac J Cancer Prev. 2014;15(2): 957-961.
53. Poynter JN, Jacobs ET, Figueiredo JC, et al. Genetic variation in the Vitamin D receptor (VDR) and the Vitamin D-binding protein (GC) and risk for colorectal cancer: Results from the Colon Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2010;19(2):525-536.
54. Zeljic K, Supic G, Stamenkovic Radak M, et al. Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival. J Oral Pathol Med. 2012;41(10):779-787.
55. Reimers LL, Crew KD, Bradshaw PT, et al. Vitamin Drelated gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. Cancer Causes Control. 2015;26(2): 187-203.
56. Karami S, Brennan P, Rosenberg PS, et al. Analysis of SNPs and haplotypes in Vitamin D pathway genes and renal cancer risk. PLoS One. 2009;4(9):e7013.
57. Deschasaux M, Souberbielle JC, Latino-Martel P, et al. Prospective associations between vitaminD status, Vitamin Drelated gene polymorphisms, and risk of tobacco-related cancers. AmJClinNutr. 2015;102(5):1207-1215.
58. Ahn J, Albanes D, Berndt SI, et al. Vitamin D-related genes, serum Vitamin D concentrations and prostate cancer risk. Carcinogenesis. 2009;30(5):769-776.
59. Anderson LN, Cotterchio M, Knight JA, et al. Genetic variants in Vitamin D pathway genes and risk of pancreas cancer; results from a population-based case-control study in Ontario, Canada. PLoS One. 2013;8(6):e66768.
60. Holick CN, Stanford JL, Kwon EM, et al. Comprehensive association analysis of the Vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(10):1990-1999.
61. Holt SK, Kwon EM, Peters U, et al. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1929-1933.
62. Fuhrman BJ, Freedman DM, Bhatti P, et al. Sunlight, polymorphisms of Vitamin D-related genes and risk of breast cancer. Anticancer Res. 2013;33(2):543-551.
63. Hiraki LT, Qu C, Hutter CM, et al. Genetic predictors of circulating 25-hydroxyvitamin D and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(11): 2037-2046.
64. Mondul AM, Shui IM, Yu K, et al. Vitamin D-Associated genetic variation and risk of breast cancer in the breast and prostate cancer cohort consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2015;24(3):627-630.
65. Mondul AM, Shui IM, Yu K, et al. Genetic variation in the Vitamin D pathway in relation to risk of prostate cancer- results from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):688-696.
66. Pilz S, Kienreich K, Tomaschitz A, et al. Vitamin D and cancer mortality: systematic review of prospective epidemiological studies. Anticancer Agents Med Chem. 2013; 13(1):107-117.
67. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and metaanalysis of observational cohort and randomised intervention studies. BMJ. 2014;348:g1903.
68. Autier P, Boniol M, Pizot C, et al. Vitamin D status and ill health: A systematic review. Lancet Diabetes Endocrinol. 2014;2(1):76-89.
69. Robsahm TE, Schwartz GG, Tretli S. The inverse relationship between 25-hydroxyvitamin D and cancer survival: discussion of causation. Cancers (Basel). 2013;5(4): 1439-1455.
70. Schöttker B, Jorde R, Peasey A, et al. Vitamin D and mortality: meta-Analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ. 2014;348:g3656.
71. Yin L, Ordonez-Mena JM, Chen T, et al. Circulating 25- hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and metaanalysis. Prev Med. 2013;57(6):753-764.
72. Michaelsson K, Baron JA, Snellman G, et al. Plasma Vitamin D and mortality in older men: A community-based prospective cohort study. Am J Clin Nutr. 2010;92(4):841-848.
73. Afzal S, Brøndum-Jacobsen P, Bojesen SE, et al. Genetically low Vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ. 2014;349:g6330.
74. El Hilali, J, de Koning, EJ, van Ballegooijen, AJ, et al. Vitamin D, PTH and the risk of overall and disease-specificmortality: Results of the Longitudinal Aging Study Amsterdam. J Steroid Biochem Mol Biol. 2016;164:386-394.
75. Khaw KT, Luben R, Wareham N. Serum25-hydroxyvitamin D, mortality, and incident cardiovascular disease, respiratory disease, cancers, and fractures: A 13-y prospective population study. Am J Clin Nutr. 2014;100(5):1361-1370.
76. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25- hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26(18):2984-2991.
77. Fedirko V, Riboli E, Tjonneland A, et al. Prediagnostic 25- hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol Biomarkers Prev. 2012;21(4):582-593.
78. Fang F, Kasperzyk JL, Shui I, et al. Prediagnostic plasma Vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011;6(4):e18625.
79. Maalmi H, Ordóñez-Mena JM, Schöttker B, et al. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-Analysis of prospective cohort studies. Eur J Cancer. 2014;50(8): 1510-1521.
80. Anic GM, Weinstein SJ, Mondul AM, et al. Serum Vitamin D, Vitamin D binding protein, and lung cancer survival. Lung Cancer. 2014;86(3):297-303.
81. Huss L, Butt S, Borgquist S, et al. Serum levels of Vitamin D, parathyroid hormone and calcium in relation to survival following breast cancer. Cancer Causes Control. 2014;25(9): 1131-1140.
82. Wesa KM, Segal NH, Cronin AM, et al. Serum 25-hydroxy Vitamin D and survival in advanced colorectal cancer: A retrospective analysis. Nutr Cancer. 2015;67(3):424-430.
83. Zgaga L, Theodoratou E, Farrington SM, et al. Plasma Vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol. 2014;32(23): 2430-2439.
84. Walentowicz-Sadlecka M, Grabiec M, Sadlecki P, et al. 25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clin Biochem. 2012;45(18):1568-1572.
85. Samimi M, Touze A, Laude H, et al. Vitamin D deficiency is associated with greater tumor size and poorer outcome in Merkel cell carcinoma patients. J Eur Acad Dermatol Venereol. 2014;28(3):298-308.
86. Cho M, Peddi PF, Ding K, et al. Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. J Transl Med. 2013;11:206.
87. Holt SK, Kolb S, Fu R, et al. Circulating levels of 25- hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013;37(5):666-670.
88. Gupta D, Trukova K, Popiel B, et al. The association between pre-Treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer. PLoS One. 2015; 10(3):e0119690.
89. Brändstedt J, Almquist M, Manjer J, et al. Vitamin D, PTH, and calcium in relation to survival following prostate cancer. Cancer Causes Control. 2016;27(5):669-677.
90. Mondul AM, Weinstein SJ, Moy KA, et al. Circulating 25- hydroxyvitamin D and prostate cancer survival. Cancer Epidemiol Biomarkers Prev. 2016;25(4):665-669.
91. Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma Vitamin D, and risk of lethal prostate cancer: A prospective nested case-control study. J Natl Cancer Inst. 2012;104(9):690-699.
92. Shui IM, Mondul AM, Lindström S, et al. Circulating Vitamin D, Vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015;121(12): 1949-1956.
93. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral Vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ. 2003; 326(7387):469.
94. Brunner RL, Wactawski-Wende J, Caan BJ, et al. The effect of calcium plus Vitamin D on risk for invasive cancer: Results of the Women's Health Initiative (WHI) calciumplus vitaminD randomized clinical trial. Nutr Cancer. 2011;63(6): 827-841.
95. Avenell A, MacLennan GS, Jenkinson DJ, et al. Long-Term follow-up for mortality and cancer in a randomized placebocontrolled trial of Vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab. 2012;97(2):614-622.
96. Lazzeroni M, Serrano D, Pilz S, et al. Vitamin D supplementation and cancer: Review of randomized controlled trials. Anticancer Agents Med Chem. 2013;13(1):118-125.
97. Komulainen M, Kroger H, Tuppurainen MT, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and Vitamin D3 in early postmenopausal women: A population-based 5-year randomized trial. J Clin Endocrinol Metab. 1999;84(2):546-552.
98. Buttigliero C, Monagheddu C, Petroni P, et al. Prognostic role of Vitamin D status and efficacy of Vitamin D supplementation in cancer patients: A systematic review. Oncologist. 2011; 16(9):1215-1227.
99. Jeffreys M, Redaniel MT, Martin RM. The effect of prediagnostic Vitamin D supplementation on cancer survival in women: A cohort study within the UK Clinical Practice Research Datalink. BMC Cancer. 2015;15:670.
100. Lewis C, Xun P, He K. Vitamin D supplementation and quality of life following diagnosis in stage II colorectal cancer patients: A 24-month prospective study. Support Care Cancer. 2016;24(4):1655-1661.
101. Perna L, Hoffmeister M, Schottker B, et al. Vitamin D receptor polymorphism and colorectal cancer-specific and allcause mortality. Cancer Epidemiol. 2013;37(6):905-907.
102. Perna L, Butterbach K, Haug U, et al. Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev. 2013;22(3):437-442.
103. Holt SK, Kwon EM, Koopmeiners JS, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010;70(13):1448-1460.
104. Pao JB, Yang YP, Huang CN, et al. VitaminD receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer. World J Urol. 2013;31(2):281-287.
105. Liu Y, Chen W, Hu ZB, et al. Plasma Vitamin D levels and Vitamin D receptor polymorphisms are associated with survival of non-small cell lung cancer. Chin J Cancer Res. 2011;23(1):33-37.
106. Orlow I, Reiner AS, Thomas NE, et al. Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: A population-based study. Carcinogenesis. 2016; 37(1):30-38.
107. Yin J, Liu H, Yi X, et al. Genetic variants in the Vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease-specific survival. Pigment Cell Melanoma Res. 2016;29(2):176-185.
108. Obara W, Suzuki Y, Kato K, et al. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. Int J Urol. 2007;14(6):483-487.
109. Anic GM, Thompson RC, Nabors LB, et al. An exploratory analysis of common genetic variants in the Vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. Cancer Causes Control. 2012;23(9):1443-1449.
110. Forrest KY, Stuhldreher WL. Prevalence and correlates of Vitamin D deficiency in US adults. Nutr Res. 2011;31(1): 48-54.
111. Freedman DM, Cahoon EK, Rajaraman P, et al. Sunlight and other determinants of circulating 25-hydroxyvitamin D levels in black and white participants in a nationwide US study. Am J Epidemiol. 2013;177(2):180-192.
112. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66(4): 290-308.
113. Armas LA, Dowell S, Akhter M, et al. Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: The effect of UVB dose and skin color. J Am Acad Dermatol. 2007;57(4): 588-593.
114. Grant WB, Mascitelli L, Goldstein MR. Differences in Vitamin D status likely explain racial disparities in breast cancer mortality rates in the Southeast [letter]. Cancer. 2012; 118(17):4363; author reply 4364.
115. Tsai CJ, Giovannucci EL. Hyperinsulinemia, insulin resistance, Vitamin D, and colorectal cancer among whites and African Americans. Dig Dis Sci. 2012;57(10): 2497-2503.
116. Batai K, Murphy AB, Nonn L, et al. Vitamin D and immune response: implications for prostate cancer in African Americans. Front Immunol. 2016;7:53.
117. Grant WB, Peiris AN. Differences in Vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans. Dermato-Endocrinology. 2012;4(2):85-94.
118. Giovannucci E, Liu Y, Willett WC. Cancer incidence and mortality and Vitamin D in black and white male health professionals. Cancer Epidemiol Biomarkers Prev. 2006; 15(12):2467-2472.
119. Fiscella K, Winters P, Tancredi D, et al. Racial disparity in death from colorectal cancer: does Vitamin D deficiency contribute? Cancer. 2011;117(5):1061-1069.
120. Jackson MD, Tulloch-Reid MK, Lindsay CM, et al. Both serum 25-hydroxyvitamin D and calcium levels may increase the risk of incident prostate cancer in Caribbean men of African ancestry. Cancer Med. 2015;4(6):925-935.
121. Paller CJ, Kanaan YM, Beyene DA, et al. Risk of prostate cancer in African-American men: Evidence of mixed effects of dietary quercetin by serum Vitamin D status. Prostate. 2015;75(13):1376-1383.
122. Beyene D, Daremipouran M, Apprey V, et al. Use of tanning potential as a predictor for prostate cancer risk in African-American men. In Vivo. 2014;28(6):1181-1187.
123. Murphy AB, Nyame Y, Martin IK, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res. 2014;20(9):2289-2299.
124. Steck SE, Arab L, Zhang H, et al. Association between plasma 25-hydroxyvitamin D, ancestry and aggressive prostate cancer among African Americans and European Americans in PCaP. PLoS One. 2015;10(4):e0125151.
125. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993;2(5):467-472.
126. Park SY, Cooney RV, Wilkens LR, et al. Plasma 25- hydroxyvitamin D and prostate cancer risk: The Multiethnic Cohort. Eur J Cancer. 2010;46(5):932-936.
127. Layne TM, Weinstein SJ, Graubard BI, et al. Serum 25- hydroxyvitamin D, Vitamin D binding protein, and prostate cancer risk in black men [published online ahead of print April 3, 2017]. Cancer. (doi:10.1002/cncr.30634).
128. Janowsky EC, Lester GE, Weinberg CR, et al. Association between low levels of 1, 25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999;2(3):283-291.
129. Woolcott CG, Wilkens LR, Nomura AM, et al. Plasma 25- hydroxyvitamin D levels and the risk of colorectal cancer: The Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev. 2010;19(1):130-134.
130. Freedman DM, Looker AC, Abnet CC, et al. Serum 25- hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res. 2010;70(21):8587-8597.
131. Kritchevsky SB, Tooze JA, Neiberg RH, et al. 25- Hydroxyvitamin D, parathyroid hormone, and mortality in black and white older adults: The Health ABC Study. J Clin Endocrinol Metab. 2012;97(11):4156-4165.
132. Fortmann SP, Burda BU, Senger CA, et al. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2013;159(12):824-834.
133. LeFevre ML; US Preventive Services Task Force. Screening for Vitamin D deficiency in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;162(2):133-140.
134. Moyer VA; US Preventive Services Task Force. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(8):558-564.
135. Moyer VA; US Preventive Services Task Force. Vitamin D and calcium supplementation to prevent fractures in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158(9):691-696.
136. Zhao S, Gardner K, Taylor W, et al. Vitamin D assessment in primary care: changing patterns of testing. London J Prim Care (Abingdon). 2015;7(2):15-22.
137. Gahche J, Bailey R, Burt V, et al. Dietary Supplement use among US adults has increased since NHANES III (1988-1994). NCHS Data Brief. 2011;(61):1-8.
138. Song M, Nishihara R, Wang M, et al. Plasma 25- hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut. 2016;65(2):296-304.
139. Albanes D. Vitamin D and cancer: diversity, complexity, and still a ways to go. Cancer Prev Res (Phila). 2015;8(8): 657-661.
140. Jacobs ET, Kohler LN, Kunihiro AG, et al. Vitamin D and colorectal, breast, and prostate cancers: A review of the epidemiological evidence. J Cancer. 2016;7(3):232-240.
141. Weinstein SJ, Mondul AM, Kopp W, et al. Circulating 25- hydroxyvitamin D, Vitamin D-binding protein and risk of prostate cancer. Int J Cancer. 2013;132(12):2940-2947.
142. Mondul AM, Weinstein SJ, Virtamo J, et al. Influence of Vitamin D binding protein on the association between circulating Vitamin D and risk of bladder cancer. Br J Cancer. 2012;107(9):1589-1594.
143. Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, et al. Impact of circulating Vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: A nested case-control study. Cancer Res. 2012; 72(5):1190-1198.
144. Al-oanzi ZH, Tuck SP, Raj N, et al. Assessment of Vitamin D status in male osteoporosis. Clin Chem. 2006;52(2):248-254.
145. Henderson CM, Lutsey PL, Misialek JR, et al. Measurement by a novel LC-MS/MS methodology reveals similar serum concentrations of Vitamin D-binding protein in blacks and whites. Clin Chem. 2016;62(1):179-187.
146. Manson JE, Bassuk SS, Lee IM, et al. The Vitamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of Vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1): 159-171.
147. Gail MH, Wu J, Wang M, et al. Calibration and seasonal adjustment for matched case-control studies of Vitamin D and cancer. Stat Med. 2016;35(13):2133-2148.
148. Fraser WD, Milan AM. Vitamin D assays: past and present debates, difficulties, and developments. Calcif Tissue Int. 2013;92(2):118-127.
149. Binkley N, Sempos CT; Vitamin D Standardization Program (VDSP). Standardizing Vitamin D assays: The way forward. J Bone Miner Res. 2014;29(8):1709-1714.